NCT07354126Recruiting
Comparative Efficacy of Flunarizine and Propanolol in Pediatric Migraine
Comparative Efficacy of Flunarizine and Propanolol in Pediatric Migraine Using the PedMIDAS Measuring Tool.
Source: ClinicalTrials.gov · Last updated 21 Jan 2026
Brief summary (registry, in English)
Flunarizine and propranolol have demonstrated efficacy in reducing migraine frequency across age groups, though evidence in pediatric populations remains limited and inconsistent. Therefore, the current study has been planned to evaluate and compare the effectiveness of flunarizine and propranolol in reducing migraine frequency in children aged 8-15 using the Pediatric Migraine Disability Assessment Scale (PedMIDAS) score.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- First submitted
- 12 Jan 2026
- Start date
- 1 Sept 2025
- Primary completion date
- 28 Feb 2026
- Lead sponsor
- Muhammad Aamir Latif
- Diseases
- Migraine
- NCT number
- NCT07354126
What you commit to
- Study type: Interventional
- Planned participants: 44
- From 1 Sept 2025 to the primary completion date, 28 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Children with secondary headache disorders (e.g., due to infections, trauma, structural brain lesions)
- Known hypersensitivity or contraindications to flunarizine or propranolol
- Presence of cardiovascular disorders (e.g., bradycardia, heart block, hypotension, asthma)
Other
- Non-compliance or inability to attend regular follow-ups
- Participation in another clinical trial within the last 3 months
Who the study is looking for
- Children of any gender
- Aged 8-15 years
- Diagnosed with migraine (with/without aura) per International Classification of Headache Disorders, 3rd Edition (ICHD-3) criteria
- A history of ≥4 migraine attacks/month for the preceding 3 months
- With a PedMIDAS score ≥11 (moderate-to-severe impact)
Age in the registry: 8 years to 15 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Children's Hospital Lahore Coordinator of this site? Confirm its status | Lahore | Pakistan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.